Steroid Receptor Expression in Endometria from Women Treated with Tamoxifen
| Autor: | Charles James Kirkpatrick, Ulrich Karck, Friedrich Kommoss, Jacobus Pfisterer, Heiner Prompeler |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Antineoplastic Agents Hormonal medicine.drug_class Receptor expression Estrogen receptor Breast Neoplasms Endometrium Breast cancer Internal medicine Endometrial Polyp Humans Medicine Retrospective Studies business.industry Obstetrics and Gynecology medicine.disease Postmenopause Tamoxifen medicine.anatomical_structure Endocrinology Receptors Estrogen Oncology Estrogen Adenocarcinoma Female Receptors Progesterone business medicine.drug |
| Zdroj: | Gynecologic Oncology. 70:188-191 |
| ISSN: | 0090-8258 |
| Popis: | Breast cancer patients receiving tamoxifen (Tam) are at an increased risk for developing endometrial carcinomas, possibly due to the partial estrogenic effect of Tam on endometrial cells. Progestational therapy has not routinely been included in Tam regimens. It was our aim to determine the presence of estrogen receptors (ERs) and progesterone receptors (PRs) in normal and abnormal endometria from postmenopausal women with breast cancer who were treated with Tam. Standard immunohistochemical staining of ERs and PRs was performed on paraffin sections from formalin-fixed uterine curettings or hysterectomy specimens from 40 patients who had received 20–40 mg of Tam daily for a minimum of 3 months. For comparison, normal endometria from 20 women who had not received Tam (11 premenopausal, 9 postmenopausal) were also studied for ER and PR expression. Staining was evaluated using semiquantitative immunoreactivity scores (IRS) ranging from 0 (negative) to 12 (strongly positive). In the group of patients receiving Tam, ERs and PRs were detected in the nuclei of glandular cells in 24/24 cases of endometrial atrophy (ER/PR-IRS, 2–12), in 8/8 endometrial polyps (ER-IRS, 6–12; PR-IRS, 4–12), in 4/4 adenomatous endometrial hyperplasias (ER-IRS, 3–8; PR-IRS, 1–12), and in 4/4 well-differentiated endometrioid adenocarcinomas (ER-IRS, 2–12; PR-IRS, 6–8). Of the 11 endometria from premenopausal patients who had not received Tam, 8 were ER+/PR+ (ER-IRS, 1–12; PR-IRS, 1–12), 1 was ER+/PR− (ER-IRS, 3; PR-IRS, 0), 1 was ER−/PR+ (ER-IRS, 0; PR-IRS, 2), and 1 was ER−/PR− (ER/PR-IRS, 0). Among 9 atrophic endometria from women not treated with Tam, 6 were ER+/PR+ (ER-IRS, 4–12; PR-IRS, 3–6), 1 was ER+/PR− (ER-IRS, 4; PR-IRS, 0), and 2 were ER−/PR− (ER/PR-IRS, 0). The consistent finding of ER and PR expression in endometria from postmenopausal women receiving Tam further supports the suspected estrogenic effect exerted by Tam on endometrial cells. Progestational therapy could be beneficial in the prevention of Tam-induced abnormal endometrial proliferations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect